Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions develops and supplies public health products and medical countermeasures for government agencies, healthcare providers, and community preparedness programs. Its news centers on products such as NARCAN® Nasal Spray for opioid overdose emergencies and ACAM2000® for smallpox and mpox, along with biodefense countermeasures for threats including anthrax, botulism, and Ebola.
Recurring updates also cover quarterly results, debt refinancing and balance-sheet actions, regulatory approvals, government supply activity, and manufacturing services. The company reports on bioservices agreements and facility utilization at sites such as Canton, Massachusetts, and Winnipeg, Manitoba, where it supports vaccine, biologic, and drug product manufacturing programs.
Emergent BioSolutions (NYSE: EBS) will host a conference call on November 4, 2021, at 5:00 PM ET to discuss Q3 2021 financial results, recent developments, and the full-year outlook. Interested parties can join via telephone or webcast. The call will provide insights into the company's financial performance and strategic direction as it aims to enhance public health. For more details, visit the Emergent website.
Emergent BioSolutions (NYSE:EBS) announced the first participant dosed in its pivotal phase 3 study for the CHIKV VLP vaccine, targeting chikungunya disease. This single-dose vaccine candidate is the only VLP-based option in clinical testing. The study aims to enroll over 3,150 participants across 49 U.S. sites, focusing on its safety and immune response. Previous phase 2 results indicated strong immunogenicity and a favorable safety profile. Regulatory agencies have granted the vaccine several designations to expedite its development, addressing an unmet medical need.
Shuman, Glenn & Stecker is investigating potential claims against Emergent BioSolutions (EBS) related to a securities class action lawsuit. The lawsuit alleges that Emergent's executives misrepresented the company's ability to produce COVID-19 vaccines, specifically those of Johnson & Johnson and AstraZeneca, at its Baltimore facility. Following FDA inspections revealing significant operational issues and contamination incidents, Emergent's stock fell over 15% in early April 2021 and has since dropped to around $55 per share, failing to recover.
Emergent BioSolutions (NYSE:EBS) and Providence Therapeutics have established a five-year agreement valued at approximately $90 million for contract development and manufacturing services to support the development of Providence’s COVID-19 mRNA vaccine, PTX-COVID19-B.
This collaboration will enable Emergent to manufacture tens of millions of doses in 2022, with potential for hundreds of millions more. The manufacturing will utilize Emergent’s cGMP facility in Winnipeg, Canada, underscoring their commitment to addressing global public health needs.
Emergent BioSolutions has announced the start of a Phase 3 clinical trial for its COVID-19 Human Immune Globulin (COVID-HIG) to assess its efficacy and safety as a treatment for high-risk adult patients. Sponsored by NIAID, the study aims to enroll about 800 patients and examines the effects of hyperimmune globulin products on combating COVID-19 progression. The trial, named OTAC, will compare COVID-HIG infusions against a placebo, focusing on improving patient outcomes and reducing severe illness risks, particularly for immunocompromised individuals and older adults.
Emergent BioSolutions (NYSE: EBS) will attend several key investor conferences, including the IDEAS Midwest Conference (Aug 25-26) and the Wells Fargo Virtual Healthcare Conference (Sept 9-10). Key activities include pre-recorded presentations and 1-on-1 meetings. The company aims to discuss recent developments and financial guidance during these events. Emergent BioSolutions focuses on protecting public health and plans to enhance the lives of 1 billion people by 2030. For further details, visit their website.
Emergent BioSolutions Inc. (NYSE: EBS) reported Q2 2021 financial results, reaffirming its 2021 revenue forecast of $1.7 - $1.9 billion. Total revenues for Q2 were $397.5 million, a slight increase of 1% YoY, while net income plummeted 95% to $4.6 million. The company resumed production of Johnson & Johnson’s COVID-19 vaccine after FDA approval and secured contracts with U.S. and Canadian governments valued at over $238 million. Adjusted EBITDA declined 68% to $49.5 million, reflecting higher costs and inventory write-offs. The company anticipates Q3 revenues between $400 million and $500 million.
Emergent BioSolutions (NYSE:EBS) announced the resumption of production at its Bayview facility for Johnson & Johnson's Covid-19 vaccine bulk drug substance, following FDA reviews and a quality enhancement plan. CEO Robert Kramer highlighted this as a critical milestone in addressing public health threats. The company committed extensive resources to meet FDA standards and aims to ensure a strong supply chain for the vaccine. Emergent positions itself as a vital partner in epidemic preparedness and expresses gratitude towards government and industry collaborators.
Emergent BioSolutions partners with national nonprofit organizations to launch the Reverse the Silence campaign, raising awareness about opioid overdoses. The initiative features stories from Darren Waller and Dani Schaffer, who share personal experiences with addiction. According to CDC data, over 93,000 Americans died from drug overdoses in 2020, with opioids involved in 80% of those deaths. The campaign aims to encourage open communication about opioid risks and promote emergency preparedness.
Emergent BioSolutions Inc. (NYSE: EBS) will hold a conference call on July 29, 2021, at 5:00 PM ET to discuss its Q2 2021 financial results and provide revenue guidance for Q3 2021 and the full year. Investors can join via phone or webcast, with access details provided. Emergent aims to enhance life through its specialty products and services dedicated to public health, aspiring to protect or enhance one billion lives by 2030. For more details, visit their official website.